Quanterix Corporation

Quanterix Corporation

QTRXNYSE / NASDAQHealthcareSmall cap

$1.96-$0.07 (-3.4%)

Last close · Data as of Nov 20, 2026

Market cap
$179.0M
P/E
-1.7x
EV / EBITDA
-2.1x
Revenue
$138.7M
Net margin
-77.3%
ROCE
-31.9%

-66.8% over the last year

Quanterix Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-27.9%
3M
-37.2%
6M
-22.2%
1Y
-66.8%
5Y
Hidden
  • This period includes a one-day price step on 9 Aug 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.07 (-3.4%) from $2.03 to $1.96 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in QTRX, bought on each weekday since 2021.

News & filings

What Quanterix filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 107 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 105.4% in fiscal 2025, 103.0 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

Read moreShow less

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Sector
Healthcare
Shares outstanding
46.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$179.0M
P/E
-1.7x
P/B
0.6x
EV / EBITDA
-2.1x
EV / Sales
1.3x
P/S
1.3x
52-week high
$8.06
52-week low
$1.96

Profitability

Operating margin
-79.2%
Net margin
-77.3%
EBITDA margin
-65.6%
ROE
-36.2%
ROCE
-31.9%
ROIC
-28.6%
ROA
-25.6%
Asset turnover
0.33

Growth

Revenue
$138.7M
Revenue growth, 1Y
2.4%
Revenue CAGR, 3Y
9.7%
Net profit growth, 1Y
178.1%
Free cash flow
-$79.8M

Solvency

Current ratio
2.84
Debt / Equity
0.13
Debt / Assets
0.09
CFO / Net profit
0.72
Cash / Market cap
16.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$138.7M
Cost of revenue$73.9M
Gross profit$64.7M
Operating expenses$174.5M
Research and development$35.9M
Selling, general and administrative$138.8M
Operating income-$109.8M
Interest and other-$2.5M
Pretax income-$112.3M
Tax and other-$5.1M
Net income-$107.2M

Revenue and net profit

Revenue grew 2.4% in FY2025; net profit is the dashed line.

Quanterix Corporation revenue and net profit by fiscal year
Quanterix Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$105.0M-$99.6M
FY2023$121.1M-$28.4M
FY2024$135.4M-$38.5M
FY2025$138.7M-$107.2M

Cash flows

FY2025: -$77.2M from operations, -$79.8M free after investment (dashed).

Quanterix Corporation operating and free cash flow by fiscal year
Quanterix Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$48.6M-$60.2M
FY2023-$18.8M-$22.7M
FY2024-$35.2M-$38.5M
FY2025-$77.2M-$79.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$138.7M+2.4%1Y
EBITDA
-$90.9M
Net profit
-$107.2M
Cash from operations
-$77.2M
Free cash flow
-$79.8M
Revenue CAGR, 3Y
9.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$138.7M-$90.9M-$107.2M-$79.8M-36.2%+2.4%+178.1%

Monthly returns

Month-by-month returns of QTRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$418.8M
Liabilities$123.0M
Equity$295.7M
Paid-in capital$873.6M
Retained earnings-$577.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; QTRX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Quanterix Corporation (this company)1.3x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Quanterix CorporationQTRXthis company$179.0M-1.7x0.6x-36.2%-2.1x
Cartesian Therapeutics, Inc.RNAC$192.4M-1.5x-1.5x103.2%-1.0x
KORU Medical Systems, Inc.KRMD$190.2M-72.1x11.2x-15.5%-85.5x
Tonix Pharmaceuticals Holding Corp.TNXP$189.4M-1.5x0.8x-50.6%0.1x
MediWound Ltd.MDWD$185.7M-7.8x4.3x-54.7%-8.8x
Stereotaxis, Inc.STXS$183.7M-8.5x13.6x-160.5%-8.5x
Journey Medical CorporationDERM$171.3M-15.0x5.4x-35.9%-51.9x
Inogen, Inc.INGN$170.8M-7.5x0.9x-11.8%-8.9x
ADC Therapeutics SAADCT$167.9M-1.2x-0.9x76.7%-0.3x
Peer median—-7.6x2.6x-25.7%-8.7x

Year-to-date ROI

QTRX since 1 January, against earlier years.

Historical volatility

QTRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Quanterix Corporation operating margin by fiscal year
Quanterix Corporation operating margin by fiscal year
DateOperating margin
FY2022-71.2%
FY2023-36.9%
FY2024-38.9%
FY2025-79.2%
LineFY2025
Cost of revenueCost Of Revenue$73.9M
Gross profitGross Profit$64.7M
Operating expensesOperating Expense$174.5M
Research and developmentResearch And Development$35.9M
Other operating expensesOther Operating Expenses-$240.0k
Rent expense supplementalRent Expense Supplemental$840.0k
Total expensesTotal Expenses$248.5M
Pretax incomePretax Income-$112.3M

Learn while you research

Academy chapters picked for Quanterix Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →